About SFA THERAPEUTICS INC
SFA Therapeutics is a biotechnology company developing investigational therapies, including SFA-002, an oral deuterated short-chain fatty acid designed to reset immunity through the gut-immune axis for the treatment of plaque psoriasis. The company is in Phase 1b clinical trials with promising safety and efficacy data.
Development of deuterated short-chain fatty acid (SCFA) therapeuticsProprietary deuteration platform for creating new chemical entities (NCEs)Conducting clinical trials for plaque psoriasis, pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to SFA THERAPEUTICS INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.